April 1st 2024
Throughout March, the FDA has approved drugs for the treatment of disease including lung, hematologic, esophageal, and gynecologic cancers.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Few Women Receive Genetic Counseling Before BRCA Testing
October 8th 2015Genetic counseling before BRCA genetic testing improves patient knowledge, understanding, and satisfaction. However, a new analysis has found that most women undergoing BRCA genetic testing did not receive counseling prior to testing, despite national guidelines and recommendations.
Endometrial Cancer on the Rise and Impacts Black Women the Most
August 21st 2015Rates of endometrial cancer continue to increase among all racial and ethnic groups, but they're rising faster among non-Hispanic black women who also have poorer outcomes when compared with their white, non-Hispanic counterparts.
Despite Improved Survival, Intraperitoneal Chemotherapy Underused in Ovarian Cancer
August 11th 2015Less than 50% of patients with ovarian cancer who could benefit from intraperitoneal chemotherapy actually receive it, despite research suggesting that this technique could improve survival for these patients.
Deborah Watkins Bruner on Side Effects From Platinum-Based Drugs in Ovarian Cancer
June 17th 2015Deborah Watkins Bruner, PhD, RN, FAAN, from the Nell Hodgson Woodruff School of Nursing at Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.
Studies Yield More Insight Into Olaparib's Role in Ovarian Cancer
April 2nd 2015Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib (Lynparza) in the treatment of women with ovarian cancer, Ursula A. Matulonis, MD, explained during a plenary session at the 2015 Society of Gynecologic Oncology's Annual Meeting on Women's Cancer.
Survival Improvement Seen With Bevacizumab in Ovarian Cancer
April 1st 2015Treatment with bevacizumab (Avastin) plus chemotherapy resulted in a non-statistically significant improvement in overall survival (OS) of nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.
NCCN Updates Ovarian Cancer Clinical Practice Guidelines
March 20th 2015Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of bevacizumab and olaparib, and intraperitoneal chemotherapy (IP), have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines in its 20th annual edition.
Hormone Replacement Therapy Associated with Increased Ovarian Cancer Risk
February 17th 2015A new analysis has shown that taking hormone replacement therapy to alleviate symptoms associated with menopause significantly increases the risk of developing the two most common types of ovarian cancer, even if the therapy is only taken for a few years.
Update on BRCA1/2: Technical and Policy Questions Arise as Testing Options Expand
January 2nd 2015As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing. In the past 18 months, the floodgates for testing options have opened, as companies seek to enter the diagnostic market in the wake of the US Supreme Court's June 2013 ruling that "naturally occurring" human genes are a "product of nature" and cannot be patented, breaking Myriad Genetics' monopoly on BRCA1/2 gene testing.